Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline

Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Klein Connolly, Maura N. Dickler, Lesley Fallowfield, Barbara Fowble, James N. Ingle, Mohammad Jahanzeb, Stephen R D Johnston, Larissa A. Korde, James L. Khatcheressian, Rita S. Mehta, Hyman B. Muss, Harold J. Burstein

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendations Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.

Original languageEnglish (US)
Pages (from-to)3069-3103
Number of pages35
JournalJournal of Clinical Oncology
Volume34
Issue number25
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Medical Oncology
Hormones
Guidelines
Breast Neoplasms
Aromatase Inhibitors
Therapeutics
exemestane
Drug Therapy
Biological Therapy
Cyclin-Dependent Kinases
Sirolimus
Tumor Biomarkers
Neoplasms
Appointments and Schedules

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., ... Burstein, H. J. (2016). Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. Journal of Clinical Oncology, 34(25), 3069-3103. https://doi.org/10.1200/JCO.2016.67.1487

Endocrine therapy for hormone receptor-positive metastatic breast cancer : American society of clinical oncology guideline. / Rugo, Hope S.; Rumble, R. Bryan; Macrae, Erin; Barton, Debra L.; Connolly, Hannah Klein; Dickler, Maura N.; Fallowfield, Lesley; Fowble, Barbara; Ingle, James N.; Jahanzeb, Mohammad; Johnston, Stephen R D; Korde, Larissa A.; Khatcheressian, James L.; Mehta, Rita S.; Muss, Hyman B.; Burstein, Harold J.

In: Journal of Clinical Oncology, Vol. 34, No. 25, 01.09.2016, p. 3069-3103.

Research output: Contribution to journalArticle

Rugo, HS, Rumble, RB, Macrae, E, Barton, DL, Connolly, HK, Dickler, MN, Fallowfield, L, Fowble, B, Ingle, JN, Jahanzeb, M, Johnston, SRD, Korde, LA, Khatcheressian, JL, Mehta, RS, Muss, HB & Burstein, HJ 2016, 'Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline', Journal of Clinical Oncology, vol. 34, no. 25, pp. 3069-3103. https://doi.org/10.1200/JCO.2016.67.1487
Rugo, Hope S. ; Rumble, R. Bryan ; Macrae, Erin ; Barton, Debra L. ; Connolly, Hannah Klein ; Dickler, Maura N. ; Fallowfield, Lesley ; Fowble, Barbara ; Ingle, James N. ; Jahanzeb, Mohammad ; Johnston, Stephen R D ; Korde, Larissa A. ; Khatcheressian, James L. ; Mehta, Rita S. ; Muss, Hyman B. ; Burstein, Harold J. / Endocrine therapy for hormone receptor-positive metastatic breast cancer : American society of clinical oncology guideline. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 25. pp. 3069-3103.
@article{a35716d9ab5249efb837b1963fe1d881,
title = "Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline",
abstract = "Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendations Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.",
author = "Rugo, {Hope S.} and Rumble, {R. Bryan} and Erin Macrae and Barton, {Debra L.} and Connolly, {Hannah Klein} and Dickler, {Maura N.} and Lesley Fallowfield and Barbara Fowble and Ingle, {James N.} and Mohammad Jahanzeb and Johnston, {Stephen R D} and Korde, {Larissa A.} and Khatcheressian, {James L.} and Mehta, {Rita S.} and Muss, {Hyman B.} and Burstein, {Harold J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1200/JCO.2016.67.1487",
language = "English (US)",
volume = "34",
pages = "3069--3103",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Endocrine therapy for hormone receptor-positive metastatic breast cancer

T2 - American society of clinical oncology guideline

AU - Rugo, Hope S.

AU - Rumble, R. Bryan

AU - Macrae, Erin

AU - Barton, Debra L.

AU - Connolly, Hannah Klein

AU - Dickler, Maura N.

AU - Fallowfield, Lesley

AU - Fowble, Barbara

AU - Ingle, James N.

AU - Jahanzeb, Mohammad

AU - Johnston, Stephen R D

AU - Korde, Larissa A.

AU - Khatcheressian, James L.

AU - Mehta, Rita S.

AU - Muss, Hyman B.

AU - Burstein, Harold J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendations Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.

AB - Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendations Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.

UR - http://www.scopus.com/inward/record.url?scp=84983472002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983472002&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.67.1487

DO - 10.1200/JCO.2016.67.1487

M3 - Article

C2 - 27217461

AN - SCOPUS:84983472002

VL - 34

SP - 3069

EP - 3103

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -